News
-
Bayer’s New $250M Cell & Gene Therapy Site Signals More Investments to Come
Bayer opens its new cell therapy manufacturing facility as it prepares a Parkinson’s disease cell therapy for Phase 2 testing. The new 100,000 square foot facility also has space for manufacturing other cell therapies in the pharma giant’s pipeline.
-
Bessemer Venture Partners Unveils State of Health Tech Report at HLTH 2023
The report maps out the health tech sector’s current position in the innovation hype cycle, which business models are most resilient, and how the industry can move out of the trough of disillusionment. It also offered predictions for health tech trends in 2024.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Why One Expert Thinks the Medicare Drug Price Negotiation Program Is Here to Stay
Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. Her reasoning? Every other high income nation has been negotiating prices with drugmakers for years, and the program is widely popular in the U.S. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH.
-
How AI Can Fix the Broken Clinical Trial Process
By combining AI with human expertise and oversight, we have the potential to revolutionize the clinical trial process—and most importantly, extend and save lives.
-
MedCity Influencers, Devices & Diagnostics, Artificial Intelligence
From Promise to Impact: The Evolution of AI in Medical Imaging for Population Health and ROI
The ultimate challenge for the broader adoption of AI in medical imaging remains the same: demonstrating to healthcare institutions that it provides a clear ROI.
-
FDA Rejection Is a Delay, Not a Detour for Alnylam’s Aim to Treat Heart Disorder
Despite an affirmative FDA advisory committee vote, the agency declined to approve Alnylam Pharmaceuticals’ Onpattro for treating the heart complications caused by a rare, inherited protein disorder. But Alnylam has other drugs candidates for the disease, including one expected to post Phase 3 data in the first half of 2024.
-
Digital Health Consolidation Is Meant To Happen, VCs say
Endless digital health solutions have emerged over the last few years. But eventually, they’ll have to consolidate — and that’s part of the cycle, investors said during a panel discussion on Sunday.
-
Bristol Myers Squibb Bolsters Its Cancer Presence With $4.8B Mirati Acquisition
Acquiring Mirati Therapeutics brings Bristol Myers Squibb Krazati, one of two FDA-approved therapies addressing a KRAS cancer mutation. The deal comes as BMS looks to add revenue-generating products as patent expirations loom for several of its cancer products.
-
How Can LLMs Be Deployed Safely in Healthcare?
Healthcare technology experts have confidence that the industry will put the right guardrails up around LLMs as it continues to develop and deploy these AI tools, they said Sunday during a panel discussion at Engage at HLTH.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Takeda to Pull Lung Cancer Drug from Market After Failed Confirmatory Study
Takeda Pharmaceutical drug Exkivity failed the confirmatory study required of its 2021 accelerated approval. Our recap of other recent regulatory developments includes a partial clinical hold on a cancer drug, a Covid-19 vaccine authorization, and several drug approvals in the U.S. and beyond.
-
MedCity Influencers, BioPharma
Fostering the Next Generation of Antisense Oligonucleotide Therapies
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works by targeting RNA to alter gene expression and control aberrant proteins in ways that traditional drugs can’t.
-
MedCity Influencers, Artificial Intelligence
Digital Hospital of the Future Streamlines Care to Reduce Burdens on Clinicians
The most successful implementations of digital solutions offer value propositions on both sides of the equation — they create value for the patient and family, while also making the clinician’s job easier and more enjoyable by saving time and eliminating ancillary duties.
-
How Are Digital Health Investors Shifting Their Focus In 2023?
The digital health sector’s quarterly investment trends seem to be stabilizing in 2023, according to a new report from Rock Health. The report noted investors are shifting their focus away from pandemic-era categories like telehealth and pharmaceutical R&D catalysts — instead, they’re interested in startups creating products for disease treatment, the improvement of nonclinical workflows and the enablement of value-based care.
-
Liquid Biopsy Startup Precede Sets Out to Make Precision Medicine More Precise
Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma drug R&D as it also develops the technology for clinical care applications.
-
Instacart Partners with Mount Sinai, Launches Co-Branded MA Plans with Alignment
Through a partnership with Mount Sinai Solutions, Instacart is offering post-operative and post-partum patients a grocery stipend. Instacart is also launching co-branded Medicare Advantage plans with Alignment Healthcare that address food insecurity issues for seniors.
-
Beyond Birth: Improving the Maternal Mental Health Crisis
In response to the urgent need for support, the federally funded National Maternal Mental Health […]
-
Headway Raises $125M, Reaches Unicorn Status
Headway closed a $125 million Series C funding round. The round brings the New York-based startup’s valuation to $1 billion, reaching unicorn status. The company connects patients to in-network therapists and helps mental health providers avoid the massive administrative burden associated with taking insurance.
-
Diana Health Snags $34M to Grow Its Network of Women’s Health Practices
Diana Health, which partners with hospitals to operate a network of maternity practices, closed a $34 million Series B funding round. The startup currently operates three women’s health practices in Tennessee. With its new funding, the company plans to open new practices in Tennessee, Florida and one other yet-to-be-announced state.
Promoted
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
